MEREO BIOPHARMA GROUP PLC Shareholders' Equity
MEREO BIOPHARMA GROUP PLC (MREO) had Shareholders' Equity of $28.65 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $28.65M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $34.05M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $40.92M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $46.60M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $28.65M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $34.05M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $40.92M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $46.60M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $54.18M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $60.08M 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $60.97M 10-Q · filed 2026-08-11 | |
| 2024-09-30 | -$72.54M 10-Q · filed 2025-11-10 | $72.54M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $78.65M 10-Q · filed 2025-11-10 | |
| 2024-03-31 | $42.84M 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $50.54M 10-K · filed 2026-03-19 | |
| 2023-09-30 | $54.71M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $49.66M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $44.40M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $51.40M 10-K · filed 2025-03-26 | |
| 2021-12-31 | $92.20M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |